BioSpace News Archive

ImmunoScape, a biotechnology company focused on next-generation T Cell receptor -based immunotherapies, announced that members of its executive team will present at two upcoming conferences, BioCentury-BayHelix East-West Summit 2024 and The State of Precision Medicine 2024.

NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Ina Sarel, the Head of CMC, Quality and Regulatory Affairs at NurExone, will be leading a workshop at the upcoming Exosome Characterization & Analytical Development Summit.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 10,250 restricted stock units to two newly-hired employees.

Oragenics, Inc. announced the closing of its previously announced underwritten public offering of 1,400,000 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $2.1 million, before deducting underwriting discounts, and offering expenses payable by the Company.

Bristol Myers Squibb announced that its Board of Directors has declared a quarterly dividend of sixty cents per share on the $0.10 par value common stock of the company.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 2,100 shares of G1’s common stock and 1,050 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

LeMaitre Vascular, Inc. announced that management will be participating in four upcoming investor conferences in March.

Adial Pharmaceuticals, Inc. announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,150,000 shares of common stock of the Company originally issued in October 2023, having an exercise price of $2.82 per share and eighteen months term.

Jacobio Pharma announced it received IND approval of its self-developed drug JAB-30300 from the FDA of the U.S. Jacobio plans to initiate a Phase I/IIa advanced solid tumors clinical trial in the U.S., to evaluate safety and efficacy of JAB-30300.

Precision BioSciences, Inc. announced that it has agreed to sell to the public by way of an underwritten offering 2,500,000 shares of its common stock and accompanying warrants to purchase up to 2,500,000 shares of common stock at a combined offering price of $16.00 price per share, for total gross proceeds of $40.0 million, before deducting underwriting discounts and commissions.